Last reviewed 2026-05-23 · How we verify

HES 130/04

K. C. Rasmussen · FDA-approved active Small molecule Under review

HES 130/04 is a Synthetic colloid / Plasma volume expander Small molecule drug developed by K. C. Rasmussen. It is currently FDA-approved for Acute blood loss and hypovolemia requiring volume replacement during surgery or trauma. Also known as: Voluven, HES 130/04, B 05 AA 07, Fresenius Kabi A/S..

HES 130/04 is a synthetic colloid that expands intravascular volume by maintaining oncotic pressure in the bloodstream.

HES 130/04, also known as Hydroxyethyl Starch 130/0.4, was studied in a clinical trial for its effect on blood loss during hip replacement arthroplasty. The trial compared HES 130/04 to Ringer's lactate for volemic expansion in this surgical context.

At a glance

Generic name	HES 130/04
Also known as	Voluven, HES 130/04, B 05 AA 07, Fresenius Kabi A/S.
Sponsor	K. C. Rasmussen
Drug class	Synthetic colloid / Plasma volume expander
Modality	Small molecule
Therapeutic area	Critical Care / Anesthesia
Phase	FDA-approved

Mechanism of action

HES 130/04 (hydroxyethyl starch with a molecular weight of 130 kDa and degree of substitution of 0.4) functions as a plasma volume expander used in fluid resuscitation. It remains in the intravascular space longer than crystalloid solutions, providing sustained hemodynamic support. The molecule's structure allows it to maintain colloid osmotic pressure, helping to restore circulating blood volume in hypovolemic states.

Approved indications

Acute blood loss and hypovolemia requiring volume replacement during surgery or trauma

Common side effects

Increased bleeding risk
Acute kidney injury
Hyperchloremic acidosis
Coagulopathy

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HES 130/04 CI brief — competitive landscape report
HES 130/04 updates RSS · CI watch RSS
K. C. Rasmussen portfolio CI

Frequently asked questions about HES 130/04

What is HES 130/04?

HES 130/04 is a Synthetic colloid / Plasma volume expander drug developed by K. C. Rasmussen, indicated for Acute blood loss and hypovolemia requiring volume replacement during surgery or trauma.

How does HES 130/04 work?

HES 130/04 is a synthetic colloid that expands intravascular volume by maintaining oncotic pressure in the bloodstream.

What is HES 130/04 used for?

HES 130/04 is indicated for Acute blood loss and hypovolemia requiring volume replacement during surgery or trauma.

Who makes HES 130/04?

HES 130/04 is developed and marketed by K. C. Rasmussen (see full K. C. Rasmussen pipeline at /company/k-c-rasmussen).

Is HES 130/04 also known as anything else?

HES 130/04 is also known as Voluven, HES 130/04, B 05 AA 07, Fresenius Kabi A/S..

What drug class is HES 130/04 in?

HES 130/04 belongs to the Synthetic colloid / Plasma volume expander class. See all Synthetic colloid / Plasma volume expander drugs at /class/synthetic-colloid-plasma-volume-expander.

What development phase is HES 130/04 in?

HES 130/04 is FDA-approved (marketed).

What are the side effects of HES 130/04?

Common side effects of HES 130/04 include Increased bleeding risk, Acute kidney injury, Hyperchloremic acidosis, Coagulopathy.

Drug class: All Synthetic colloid / Plasma volume expander drugs
Manufacturer: K. C. Rasmussen — full pipeline
Therapeutic area: All drugs in Critical Care / Anesthesia
Indication: Drugs for Acute blood loss and hypovolemia requiring volume replacement during surgery or trauma
Also known as: Voluven, HES 130/04, B 05 AA 07, Fresenius Kabi A/S.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing